Clinical Research Directory

Inclusion Criteria: 1. Inpatients or outpatients aged 50-90 years; 2. Patients diagnosed with amnestic mild cognitive impairment (aMCI) due to AD or mild dementia due to AD, based on the 2018 NIA-AA clinical diagnostic criteria established by the National Institute on Aging and the Alzheimer's Association; 3. Neuropsychological assessment showing MMSE scores between 18 and 26, and a CDR score of 0.5 or 1; 4. Able to communicate fluently in Chinese (non-illiterate); 5. For those currently receiving cholinesterase inhibitor therapy (e.g., donepezil or rivastigmine), the treatment dose must be stable, defined as a fixed dosage administered continuously for at least six weeks, with no adjustment of the medication regimen during the study period; 6. Provision of written informed consent. Exclusion Criteria: 1. Documented history of cerebrovascular stroke, with clear neurological deficits at onset and corresponding responsible lesions on neuroimaging; 2. Moderate to severe white matter lesions (Fazekas score 3-6); 3. Presence of any cause of consciousness disorder; 4. Severe aphasia or motor disability that prevents completion of neuropsychological assessments; 5. Current psychiatric disorders; 6. History of alcohol dependence, drug addiction, traumatic brain injury, epilepsy, encephalitis, normal-pressure hydrocephalus, or other neurological disorders that may cause cognitive impairment; 7. Systemic diseases that may contribute to mild cognitive impairment (e.g., hepatic or renal insufficiency, endocrine disorders, vitamin deficiencies); 8. Considered unsuitable for participation by the investigators.